BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30866171)

  • 1. An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
    Lenouvel D; González-Moles MÁ; Talbaoui A; Ramos-García P; González-Ruiz L; Ruiz-Ávila I; Gil-Montoya JA
    Oral Dis; 2020 Apr; 26(3):511-526. PubMed ID: 30866171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
    Straub M; Drecoll E; Pfarr N; Weichert W; Langer R; Hapfelmeier A; Götz C; Wolff KD; Kolk A; Specht K
    Oncotarget; 2016 Mar; 7(11):12024-34. PubMed ID: 26918453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
    De Meulenaere A; Vermassen T; Aspeslagh S; Huvenne W; Van Dorpe J; Ferdinande L; Rottey S
    Oral Oncol; 2017 Jul; 70():34-42. PubMed ID: 28622889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
    Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
    Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
    Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
    Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
    Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
    Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
    Wu Q; Zhao Y; Sun Y; Yan X; Wang P
    Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.
    Jingjing W; Wenzheng G; Donghua W; Guangyu H; Aiping Z; Wenjuan W
    Cancer Med; 2018 Aug; 7(8):4004-4011. PubMed ID: 29992764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
    Kim HR; Ha SJ; Hong MH; Heo SJ; Koh YW; Choi EC; Kim EK; Pyo KH; Jung I; Seo D; Choi J; Cho BC; Yoon SO
    Sci Rep; 2016 Nov; 6():36956. PubMed ID: 27841362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
    de Vicente JC; Rodríguez-Santamarta T; Rodrigo JP; Blanco-Lorenzo V; Allonca E; García-Pedrero JM
    Cancer Epidemiol Biomarkers Prev; 2019 Mar; 28(3):546-554. PubMed ID: 30487133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
    Moratin J; Metzger K; Safaltin A; Herpel E; Hoffmann J; Freier K; Hess J; Horn D
    Head Neck; 2019 Aug; 41(8):2484-2491. PubMed ID: 30821864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD/L1 in oral squamous cell carcinoma.
    Ragos V; Mastronikolis NS; Tsiambas E; Fotiades PP
    J BUON; 2018; 23(3):835-836. PubMed ID: 30003761
    [No Abstract]   [Full Text] [Related]  

  • 16. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
    Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
    J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
    Lee Y; Shin JH; Longmire M; Wang H; Kohrt HE; Chang HY; Sunwoo JB
    Clin Cancer Res; 2016 Jul; 22(14):3571-81. PubMed ID: 26864211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.